Tudor Investment Corp
TVTX icon

Tudor Investment Corp’s Travere Therapeutics TVTX Stock Holding History

Tudor Investment Corp’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$991K Sell
33,361
-28,825
-46% -$862K ﹤0.01% 2380
2025
Q4 		$2.38M Sell
62,186
-33,561
-35% -$1.09M ﹤0.01% 1692
2025
Q3 		$2.29M Sell
95,747
-105,761
-52% -$1.99M ﹤0.01% 1713
2025
Q2 		$2.98M Buy
201,508
+38,130
+23% +$632K 0.01% 1395
2025
Q1 		$2.93M Buy
163,378
+120,165
+278% +$2.44M 0.01% 1098
2024
Q4 		$753K Buy
43,213
+5,069
+13% +$89.7K ﹤0.01% 1938
2024
Q3 		$534K Buy
38,144
+861
+2% +$8.97K ﹤0.01% 1994
2024
Q2 		$306K Sell
37,283
-103
-0.3% -$694 ﹤0.01% 2003
2024
Q1 		$288K Buy
+37,386
New +$315K ﹤0.01% 1876
2023
Q4 		– Sell
-47,195
Closed -$422K – 2918
2023
Q3 		$422K Sell
47,195
-6,047
-11% -$85.3K ﹤0.01% 1757
2023
Q2 		$818K Sell
53,242
-13,528
-20% -$246K 0.01% 1423
2023
Q1 		$1.5M Buy
66,770
+39,766
+147% +$845K 0.02% 956
2022
Q4 		$568K Sell
27,004
-4,908
-15% -$104K 0.01% 1498
2022
Q3 		$786K Buy
+31,912
New +$824K 0.02% 1085
2022
Q2 		– Sell
-83,437
Closed -$2.15M – 2519
2022
Q1 		$2.15M Buy
83,437
+20,928
+33% +$556K 0.05% 514
2021
Q4 		$1.94M Buy
62,509
+5,757
+10% +$162K 0.03% 645
2021
Q3 		$1.38M Sell
56,752
-23,315
-29% -$428K 0.02% 947
2021
Q2 		$1.17M Buy
+80,067
New +$1.58M 0.02% 793
2020
Q4 		– Sell
-13,138
Closed -$243K – 1639
2020
Q3 		$243K Sell
13,138
-55,482
-81% -$1.08M 0.01% 1066
2020
Q2 		$1.4M Sell
68,620
-11,504
-14% -$183K 0.07% 362
2020
Q1 		$1.17M Sell
80,124
-16,991
-17% -$256K 0.1% 208
2019
Q4 		$1.38M Sell
97,115
-1,370
-1% -$17.5K 0.06% 411
2019
Q3 		$1.14M Buy
98,485
+37,369
+61% +$618K 0.04% 453
2019
Q2 		$1.23M Buy
61,116
+80
+0.1% +$1.58K 0.04% 466
2019
Q1 		$1.38M Buy
61,036
+14,440
+31% +$319K 0.06% 371
2018
Q4 		$1.05M Buy
46,596
+58
+0.1% +$1.44K 0.02% 369
2018
Q3 		$1.34M Sell
46,538
-17,932
-28% -$513K 0.03% 381
2018
Q2 		$1.76M Buy
64,470
+32,999
+105% +$879K 0.06% 279
2018
Q1 		$704K Buy
31,471
+3,213
+11% +$76.5K 0.02% 449
2017
Q4 		$595K Sell
28,258
-547
-2% -$12.5K 0.02% 534
2017
Q3 		$717K Sell
28,805
-9,426
-25% -$208K 0.02% 516
2017
Q2 		$741K Sell
38,231
-23,502
-38% -$426K 0.02% 434
2017
Q1 		$1.14M Buy
61,733
+10,067
+19% +$197K 0.04% 334
2016
Q4 		$978K Sell
51,666
-14,547
-22% -$298K 0.03% 374
2016
Q3 		$1.48M Buy
66,213
+28,246
+74% +$538K 0.03% 283
2016
Q2 		$676K Buy
37,967
+13,802
+57% +$223K 0.01% 646
2016
Q1 		$330K Sell
24,165
-2,500
-9% -$37.9K 0.01% 1234
2015
Q4 		$514K Sell
26,665
-14,143
-35% -$283K 0.01% 857
2015
Q3 		$827K Buy
40,808
+13,903
+52% +$412K 0.03% 473
2015
Q2 		$892K Buy
+26,905
New +$737K 0.03% 477

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Tudor Investment Corp's TVTX Position: Q1 2026 in Review

Tudor Investment Corp reduced its Travere Therapeutics (TVTX) stake by 46% in Q1 2026, selling an estimated $862K and leaving 33,361 shares worth $991K. The position accounts for ﹤0.01% of the portfolio, ranked #2380.

Tudor Investment Corp first reported a position in TVTX in Q2 2015 and has held it in 40 quarters since. The position peaked at $2.98M in Q2 2025. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • Tudor Investment Corp held 33,361 shares of Travere Therapeutics worth $991K as of Q1 2026.
  • Tudor Investment Corp sold 28,825 Travere Therapeutics shares in Q1 2026, an estimated $862K.
  • Travere Therapeutics made up ﹤0.01% of Tudor Investment Corp's portfolio in Q1 2026, its #2380 holding.
  • Tudor Investment Corp first reported a position in Travere Therapeutics in Q2 2015 and has held it in 40 quarters since.
  • Tudor Investment Corp's Travere Therapeutics position peaked at $2.98M in Q2 2025.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Tudor Investment Corp's 13F filing for Q1 2026, filed 15 May 2026.